ESOPJul 2, 2026, 04:02 PM
Inhibikase Grants 981,243 Stock Options to New Employees
AI Summary
Inhibikase Therapeutics, Inc. announced the grant of non-qualified stock options for an aggregate of 981,243 shares of common stock to seven newly-hired non-executive employees. These grants were made under the Company’s 2026 Inducement Equity Plan, effective June 30, 2026, with an exercise price of $2.03 per share. The options vest 25% on the first anniversary and the remainder in 36 equal monthly installments.
Key Highlights
- Inhibikase granted 981,243 non-qualified stock options.
- Options were granted to seven newly-hired non-executive employees.
- Granted under the Company’s 2026 Inducement Equity Plan.
- Exercise price set at $2.03 per share, matching closing price.
- Options have a ten-year term.
- Vesting: 25% on first anniversary, then 36 equal monthly installments.
- Grants were approved by the Compensation Committee.
Price Impact
More from IKT